Blood and Marrow Transplant

Non Hodgkin's Lymphoma

Match Related Donor
- Not Eligible for Full Dose Conditioning
- High Dose Chemotherapy Required

Mycosis Fungoides/Sezary Syndrome
- BMT288
  - Phase II
  - Allogeneic CD8 Memory T-Cells
  - Infusion as Consolidative Tx After HCT in Leukemia & Lymphoma
  - PI: Lowsky Stanford

BMT236
- Phase II/III MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional or Regulatory T Cells
  - PI: Meyer NIH

BMT206
- Phase II
  - Non-myeloablative Allogeneic Transplant Using TLI & ATG in Cutaneous T Cell Lymphoma
  - PI: Weng Stanford

Unrelated Donor
- Mycosis Fungoides/Sezary Syndrome
- ≥ 18 Yrs

Autologous Donor
- CCT5001
  - Phase I
  - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Recurrent/Refractory B Cell Malignancies
  - PI: Miklos Stanford
  - 1st Priority

CCT5006-EXP
- Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant-imeligible Aggressive NHL
  - PI: Miklos Kite Pharma
  - 2nd Priority

CCT5016
- Managed Access Program (MAP) CTL019 in ALL or DLBCL
  - PI: Midos
  - Sponsor: Pending

Mantle Cell Lymphoma
- Ibrutinib Resistance

Histocompatible donor
- BMT330
  - Phase II
  - Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and Anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
  - PI: Muffy
  - Pending

- BMT310
  - Phase II
  - KTE-C19 in Relapsed/Refractory Mantle Cell Lymphoma
  - PI: Miklos Kite Pharma

- BMT316
  - Phase II
  - Optimizing Post-Allogeneic HCT Outcomes in Lymphoma Using Ibrutinib
  - PI: Miklos Vanderbilt University

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Trial Posting
- Immunotherapy